Skip to main content
. 2023 Oct;16(5):658–670. doi: 10.1016/j.mucimm.2023.07.001

Fig. 4.

Fig. 4

Bcl-2 is a key regulator of LTi-like ILC3 survival. (A) Heatmap showing the relative expression levels of Bcl-2 family members determined via bulk RNA-sequencing of NCR+ ILC3 and LTi-like ILC3 from SiLP. (B–C) Bcl-2 expression of NCR+ ILC3 and LTi-like ILC3 in SiLP. (D) Bcl-2 and Ki-67 expression in LTi-like ILC3 in SiLP from naïve or IL-2C treated mice. (E) Bcl-2 MFI in Ki-67− and Ki-67+ populations of NCR+ ILC3 and LTi-like ILC3 in SiLP from IL-2C treated mice. (F–G) Frequency and cell counts of LTi-like ILC3 in SiLP ± ABT-199 treatment ex vivo. (H–K) Frequency of active caspase 3 expression (H–I) and live/dead dye acquisition (J–K) in LTi-like ILC3 in SiLP ± ABT-199 treatment ex vivo. RNA-sequencing data (A) shown as Z-scores relative to overall average. ILC3 subsets in panels B–G identified via gating strategy in Supplementary Fig. S1A, panels H–K as in Supplementary Fig. S1B. Data shown as mean ± standard error of mean (C) or individual data points (E, G, I, K) and represent two (I) or three independent experiments (C, E, G and K) (n = 5–10). Numbers in flow plot indicate percentage of cells in the respective gate. Data in panels E, G, I and K represent paired samples from same animals with or without treatment. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 using unpaired t test (C) or paired t test (E, G, I, K). Bcl-2 = B cell lymphoma 2; DN = double negative; ILC3 = group 3 innate lymphoid cell; IL-2C = interleukin-2 complex; LTi-like = lymphoid tissue-inducer-like; MFI = mean fluorescence intensity; ns = not significant; NCR = natural cytotoxicity receptor-expressing.